Functional RNAi and CRISPR Screening and Drug Target & Biomarker Discovery
Cellecta Inc., a functional genomics solutions provider, focuses primarily on developing and implementing flexible and scalable broad-based screening and analysis approaches for drug target and biomarker discovery. Our high-throughput functional genetic screening portfolio includes:
- shRNA and CRISPR screening services
- custom and off-the-shelf pooled libraries
- knockout and knockdown cell lines
that facilitate genome-wide functional screening and the identification and validation of genes involved in critical biological and disease pathways.
With Driver-Map™ Targeted Gene Expression Profiling Service, Cellecta offers a quantitative, multiplexed approach that allows simultaneous profiling of all human protein-coding genes in one reaction, thereby providing a reliable, accurate transcriptome profile with ultra-high sensitivity.
16th Annual World Preclinical Congress (WPC), The Westin Copley Place, Boston, MA, June 12-16, 2017
Presentation – June 13, 2017, 11:50 a.m., Poster Session, Booth 313.
EACR-AACR-SIC Special Conference 2017: The Challenges of Optimizing Immuno- and Targeted Therapies: From Cancer Biology to the Clinic, Firenze Fiera, Florence, Italy, June 24-27, 2017
Poster Abstract # 105.
With Driver-Map, Cellecta offers a novel, comprehensive end-to-end service portfolio for identifying differential gene expression, mapping of clinically actionable mutations in RNA, detecting cellular composition, and profiling immunotherapy targets.
We’ll perform any or all steps, from RNAi and CRISPR screening to NGS to data analysis. Cellecta specializes in negative screens (i.e. viability or drop-out) to identify cancer drug targets.